March 13 (Reuters) - The U.S Food and Drug Administration has approved the expanded use of Mirum Pharmaceuticals' oral drug to treat itching caused by a liver disorder in patients aged five years and older, the company said on Wednesday. (Reporting by Puyaan Singh, Pratik Jain and Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.83 USD | +3.15% | +0.90% | -12.50% |
05-08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.50% | 1.22B | |
+23.37% | 47.02B | |
+48.83% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- US FDA approves expanded use of Mirum's liver disease drug